RecruitingNCT05356039
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer - a Multicenter Prospective Observational Study
Sponsor
Umeå University
Enrollment
300 participants
Start Date
Apr 19, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Confirmed or suspected invasive pancreatic primary tumor
- Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines
Exclusion Criteria6
- Suspected endocrine tumor
- Suspected non-pancreatic periampullary tumor
- Distant metastasis
- Age \< 18 years
- Patient unable to understand verbal or written information interfering with informed consent or treatment
- Mental or organic disorder interfering with informed consent or treatments
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05356039
Related Trials
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT0417253244 locations
Autologous CAR-T Cells Targeting B7-H3 in PDAC
NCT061581391 location
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
NCT052937561 location
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Aromatherapy for Mental Health Promotion in IVF Patients
NCT074806681 location